Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 6/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12248366 | 0.72 | HCRTR1 (0.36) | HCRTR1 | |
| SCHEMBL24921539 | 0.72 | SIRT6 (0.39) | — | |
| SCHEMBL30180868 | 0.71 | GRIN2D (0.45) | HCRTR1HCRTR2GPR119 | |
| SCHEMBL10136885 | 0.71 | KDM4E (0.50) | ADORA1TLR7 | |
| SCHEMBL82304 | 0.71 | — | — | |
| SCHEMBL24921063 | 0.69 | MAPT (0.32) | — | |
| SCHEMBL28465086 | 0.68 | KDM4E (0.45) | — | |
| SCHEMBL233586 | 0.68 | ALDH1A1 (0.41) | KCNH2GPR119 | |
| SCHEMBL29907617 | 0.68 | KCNJ1 (0.50) | — | |
| SCHEMBL12638947 | 0.68 | MEN1 (0.40) | KCNH2GPR119CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305672-B1 | SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING ß-SECRETASE-INHIBITING ACTIVITY | SHIONOGI & CO (JP) | 2019-03-27 | — | — | EP | disclosed |
| US-20110237576-A1 | 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| WO-2010047372-A1 | 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY | 塩野義製薬株式会社 (JP) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237576-A1 | 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY | BACE1, APP, BACE2 | HCRTR1 1057/4885HCRTR2 921/4885KCNH2 2109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.